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Abstract Previous reports have demonstrated that tetanus
toxin (TeTx) induces activation and down-regulation of protein
kinase C (PKC). In the present work the differential activation of
PKC isoforms and of signal transduction pathways, including
nerve growth factor receptor trkA, phospholipase CQ-1 (PLCQ-
1), and extracellular regulated kinases 1 and 2 (ERK-1/2) by
TeTx in a synaptosome-enriched P2 fraction from rat brain is
reported. TeTx induces clear translocation from the soluble
(cytosolic) compartment to the particulate (membranous) com-
partment of PKC-L, -Q and -N isoforms, whereas PKC-O showed a
slight decrease of its soluble fraction immunoreactivity. On the
contrary, the PKC-j isoform shows no consistent response,
whereas down-regulation of total PKC-K immunoreactivity is
shown. Immunoprecipitation assays against phosphotyrosine
show an increase of trkA and PLCQ-1 phosphorylation. More-
over, trkA activation is corroborated using phospho-specific
antibodies against phosphorylated trkA. On the other hand,
TeTx-induced stimulation of mitogen-activated protein (MAP)
kinase activity is observed, this event also being detected by
Western analysis using phospho-specific antibodies against ERK-
1/2. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Tetanus toxin (TeTx), a holoprotein with Zn2-dependent
proteasic activity produced by some strains of the Clostridium
tetani bacilli, is one of the most known lethal toxins [1]. TeTx
is synthesized as a single polypeptide chain of 150 kDa and is
subsequently activated by a bacterial endopeptidase to gener-
ate a dipeptide toxin. The main targets of TeTx are both the
central and peripheral nervous systems (for review, see [2]),
where inhibition of neurotransmitter release occurs, by means
of selective cleavage of Synaptobrevin II, a protein involved in
synaptic vesicle docking and neurotransmitter release [3,4].
Other molecular mechanisms underlying TeTx toxicity have
recently been proposed, such as the activation of Ca2-depen-
dent, GTP-modulated transglutaminase [5], or those described
by our group, i.e. activation and subsequent down-regulation
of protein kinase C (PKC) after intracerebral injection of
TeTx into adult and neonatal rat brain [6,7]. The increase
of inositol phospholipid hydrolysis in rat cerebral cortex prep-
arations treated with TeTx indicates an activation of phos-
pholipases, an e¡ect directly related to PKC activation [8].
Nerve growth factor (NGF) belongs to the neurotrophin
family [9] and exerts its e¡ects through the interaction with
the trkA membrane receptor (reviewed in [10]), activating the
protein kinase intrinsic to the receptor leading to autophos-
phorylation in tyrosine (Tyr) residues of the receptor. This
allows recognition of the receptor by several intracellular sig-
naling proteins that contain src homology (SH2) domains,
such as phospholipase CQ-1, shc proteins and the p85 PI-3
kinase subunit (reviewed in [11]). Such interactions lead to
the activation of Ras (a low molecular weight G protein)
and of Raf kinase, which in turn phosphorylates and activates
MEK (MAP kinase kinase or ERK kinase) [12]. This enzyme
then phosphorylates ERK (extracellular regulated kinase), a
family of Ser/Thr protein kinases of which the best character-
ized members are ERK-1 (p44) and ERK-2 (p42), being phos-
phorylated in Thr and Tyr residues [13].
PKC is a family of protein Ser/Thr kinases, especially abun-
dant in the nervous system, composed of homologous iso-
forms which can be divided into three subfamilies, based on
their requirement for calcium, their susceptibility to phorbol
ester-induced down-regulation and their structure [14]. Mem-
bers of the classical group (cPKC), K, LI, LII and Q isoforms,
are dependent on calcium and diacylglycerol for activation.
On the other hand, the novel isoforms (nPKC), N, O, a and
R, lack the C2 calcium binding domain common to the cPKC
members and are thus calcium-independent. Atypical (aPKC)
j, S, V and W isoforms also lack the C2, as well as one of the
repeated Cys-rich zinc binding motifs within the C1 domain
[15], being unable to bind phorbol esters, such as 12-O-tetra-
decanoyl-phorbol-13-acetate (TPA). They are, therefore, resis-
tant to phorbol ester-induced down-regulation. TPA, as well
as the physiological activators, can cause the translocation of
PKC activity from the cytosolic fraction to the membrane
[16], initially resulting in activation, but followed, in some
cases, by down-regulation, by means of a not yet well-known
proteolytic pathway [17]. This e¡ect is not only seen in re-
sponse to TPA but also to some physiological events, such as
dopamine D1 receptor stimulation in rat hippocampal slices
[18].
In the present paper, the existence of a di¡erential activa-
tion of PKC isoenzymes by TeTx, as well as the stimulation of
PLCQ-1 Tyr phosphorylation has been determined. Since
PLCQ-1 activation occurs as a result of its interaction with
Tyr kinase membrane receptors, we have addressed trkA ac-
tivation through its Tyr content. The parallel activation of
ERK-1/2 is another ¢nding that points to the triggering of
signal transduction pathways by TeTx.
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2. Materials and methods
2.1. Materials
Polyclonal antibodies against PKC isoforms K, Q and j, as well as
Protein A-agarose beads were purchased from Boehringer Mannheim
GmbH (Mannheim, Germany). The speci¢c antibody against phos-
photyrosine (Clone PY20) was obtained from Zymed Laboratories
Inc. (San Francisco, CA, USA). Monoclonal antibody against phos-
pholipase CQ-1 and polyclonal anti-trkA were from Upstate Biotech-
nology (Lake Placid, NY, USA). Phospho-p44/42 MAP kinase (ERK-
1/2) E10 monoclonal antibody and polyclonal phospho-speci¢c trkA
(Tyr-490) antibody were from New England BioLabs (Beverly, MA,
USA). Monoclonal antibody against ERK-1 and anti-mouse and anti-
rabbit secondary antibodies conjugated with horseradish peroxidase,
as well as monoclonal antibodies against PKC isoforms L, N and O
were from Transduction Laboratories (Lexington, KY, USA). Despite
ERK-1 antibody being described as speci¢c for this kinase, it also
detects ERK-2, although with less potency. [Q-32P]ATP was from
Amersham International (Buckinghamshire, UK). NGF 2.5S was sup-
plied by Alomone Labs (Jerusalem, Israel) and TeTx by List Biolog-
ical (Campbell, CA, USA). All other reagents were of the highest
grade possible from standard commercial sources.
2.2. Preparation of synaptosomes from rat brain
All experiments were performed with a crude synaptosomal fraction
(P2) prepared from Sprague-Dawley, 4^6 weeks old rat brains accord-
ing to [19] with slight modi¢cations. The whole brain was homoge-
nized in 40 vol. (wt./vol.) of phosphate bu¡er at pH 7.4 supplemented
with 0.32 M sucrose. Homogenization was performed with 12 strokes
(900 rpm) using a Potter homogenizer with a Te£on pestle (0.1^0.15
mm clearance). The homogenate was centrifuged at 4‡C for 5 min at
1000Ug. The resultant supernatant was centrifuged at 12 000Ug for
20 min. The crude synaptosomal pellet obtained from one brain was
gently resuspended in 7 ml of Krebs^Ringer bicarbonate bu¡er con-
taining 125 mM NaCl, 3 mM KCl, 1.2 mM MgSO4, 1.2 mM CaCl2,
22 mM NaHCO3, 1 mM NaH2PO4 and 10 mM glucose, and the
bu¡er was gassed before use with a mixture of 95% O2 and 5%
CO2 for 20 min and adjusted to pH 7.4.
2.3. Subcellular fractionation
When subcellular fractionation was required, synaptosomes were
collected by centrifugation after each treatment and resuspended in
0.5 ml of homogenization bu¡er containing 20 mM Tris^HCl (pH
7.5), 2 mM EDTA, 0.5 mM EGTA, 2 mM dithiothreitol (DTT),
1 mM Na3VO4, 50 mM NaF, 2 mM phenylmethyl sulphonyl £uoride
(PMSF), 10 Wg/ml leupeptin and 25 Wg/ml aprotinin and disrupted by
sonication in a Dynatech Sonic Dismembrator. The homogenate was
centrifuged for 1 h at 100 000Ug to separate the soluble fraction,
corresponding to the cytosolic compartment, from the particulate
fraction, corresponding to the membranous compartment. The pre-
cipitated fraction was further resuspended to the original volume us-
ing homogenization bu¡er supplemented with Triton X-100 (0.3%
¢nal concentration) and subsequently sonicated and incubated for
1 h at 4‡C. The extract was centrifuged for 1 h at 100 000Ug and
the resulting supernatant was considered as the particulate fraction.
Protein concentration was determined according to Bradford (1976)
using bovine serum albumin (BSA) as the standard.
2.4. Immunoprecipitation and immunoblotting analysis
The synaptosome suspension was diluted to a ¢nal protein concen-
tration of 1 mg/ml and split into the necessary aliquots. After treat-
ment, synaptosomes were collected by centrifugation and the reaction
medium was eliminated. Next, 1 ml of homogenization bu¡er supple-
mented with 0.3% Triton X-100 was added and synaptosomes were
disrupted by sonication (3U10 s). For immunoprecipitation, 1 mg of
protein was incubated by gently rocking at 4‡C overnight in the pres-
ence of 4 Wg of antibody. The immunocomplex was then captured by
adding 50 Wl of washed Protein A-agarose bead slurry (25 Wl of
packed beads) and gently rocked at room temperature for 2 h. The
agarose beads were collected by pulsing in a microcentrifuge and the
supernatant was then drained o¡. The beads were washed three times
with ice-cold PBS and resuspended in 100 Wl 2Ureducing sample bu¡-
er and boiled for 2 min. Next, the agarose beads were separated by
pulsing, and 15 Wl of each sample were analyzed in polyacrylamide gel
electrophoresis in the presence of sodium dodecyl sulfate (SDS^
PAGE), according to Laemmli (1970). All of the electrophoresis re-
agents were of analytical grade (Pharmacia Biotech, Upsala, Sweden).
The separated proteins were transferred to a polyvinylidene £uoride
(PVDF) membrane (from Millipore, Bedford, MA, USA), using a
Mini TransBlot Cell II (Bio-Rad, CA, USA) at 100 V for 1 h. The
blotting bu¡er used contained 48 mM Tris, 39 mM glycine, 1.3 mM
SDS and 20% methanol (pH 8.3). The membrane ¢lters were blocked
for 1 h with PBS supplemented with 0.1% Tween 20 and 5% defatted
Fig. 1. PKC isoform subcellular distribution in rat brain synapto-
somes and their response to TPA. Synaptosomes were exposed to
100 nM TPA for 5 min, and denatured soluble and particulate frac-
tions were prepared as described in Section 2. For SDS^PAGE,
protein loading was 20 Wg/ml and then transfer of protein to PVDF
membrane was carried out with ECL detection. Experiments were
carried out on eight separate occasions with similar results. Western
blots show representative immunodetections of PKC-K, -L, -Q, -N, -O
and -j isoforms in soluble (lines 1 and 3) or in particulate fraction
(lines 2 and 4), lines 1 and 2 being from vehicle-treated synapto-
somes and lines 3 and 4 from TPA-treated synaptosomes. The stan-
dard molecular weight is shown on the right in kDa.
C
Fig. 2. TeTx-induced PKC isoform translocation. Synaptosomes were exposed to 1, 10 and 100 nM TeTx for 15 min, and then soluble and
particulate fractions were prepared. For SDS^PAGE, protein loading was 20 Wg/lane for both fractions. Following SDS^PAGE and transfer of
protein to PVDF membrane, immunoblotting was carried out as described in Section 2 with ECL detection. The upper panels show representa-
tive blottings of the results obtained with each isoform (PKC-K, -L, -Q, -N, -O and -j), as is indicated on the left of each blot. The lower panels
show the quantitation by laser scanning densitometry of the immunoreactivity variations in the soluble (a) and particulate (b) fractions. Data
were normalized, taking the control soluble arbitrary absorbance units value as 100%. The amounts of immunoreactive PKC isoform in the
soluble or particulate fraction (expressed as %, with respect to control soluble) were plotted against log TeTx concentration. Data from three
separate experiments were expressed as means þ S.D.
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powdered milk. Next, the membranes were incubated overnight with
the corresponding antibody diluted in blocking bu¡er. Then, the
membrane ¢lters were incubated for 1 h with a secondary antibody
conjugated with horseradish peroxidase diluted in blocking bu¡er.
Several washes with PBS/0.1% Tween 20 were performed between
each one of the steps. The Western blots were developed using Super-
Signal West Pico Chemiluminescent Substrate from Pierce (Rockford,
IL, USA) and exposed to Amersham ECL ¢lms. The computer-as-
sisted analysis of the bands was performed with a Bio-Rad GS700
system (Bio-Rad, CA, USA), and data were processed with a Bio-Rad
Molecular Analyst image program using a DELL work station. Re-
peated scans were taken for ¢lm non-linearity corrections.
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2.5. MAP kinase assay
MAP kinase assays were performed as described [20], with modi¢-
cations. Brie£y, 15 Wl of soluble fraction (at a protein concentration of
40 Wg/ml) was added to 35 Wl of a solution containing MBP (0.3
mg/ml), 20 mM Tris^HCl pH 7.5, 200 WM ATP (with [Q32]ATP at a
speci¢c radioactivity of 10 000 cpm/pmol), 25 mM magnesium acetate,
2 WM PKi, 200 WM Na3VO4 and 200 WM EGTA. The phosphoryla-
tion reaction was conducted at 37‡C for 10 min. In order to terminate
the reaction, 40 Wl of the reaction solution were absorbed in phos-
phocellulose P81 Whatman paper (2 cmU2 cm), rinsed in 0.5% phos-
phoric acid and washed ¢ve times (1 min each). After that, the radio-
activity incorporated was determined by liquid scintillation counting.
3. Results
3.1. Redistribution of PKC isoforms by TPA in the rat brain
synaptosomal fraction
The classical PKC isoforms (PKC-K, -L and -Q), as well as
PKC-N, were detected in rat brain synaptosomes, appearing in
SDS^PAGE at an apparent molecular weight of 80 kDa,
whereas novel PKC-O showed an apparent molecular mass
of 110 kDa, and atypical PKC-j a molecular mass of 68
kDa. The speci¢city of the antibody against the PKC-j iso-
form has been tested through blocking the antibody with the
corresponding antigenic peptide, amino acids 577^592 of
PKC-j, since it is the only antibody that recognizes more
than one band (Fig. 1). The incubation of 100 nM TPA for
5 min induces translocation from the soluble fraction to the
particulate fraction of the classical isoforms (PKC-K, -L, -Q),
as well as the translocation of the novel PKC-N, indicating
activation of these isoforms by TPA. A large amount of
PKC-O was found associated to the particulate fraction under
basal conditions in synaptosomes, and no translocation of this
isoform was detected, although a visible diminution in the
soluble fraction was seen. In contrast, no e¡ect was observed
in the case of the PKC-j, as has been extensively described
(Fig. 1).
3.2. E¡ect of TeTx treatment on speci¢c PKC isoform
redistribution
Clear translocation of PKC-L, -Q and -N isoforms was ob-
served when synaptosomes were incubated with increasing
concentrations of TeTx, during 15 min. PKC-L is the more
sensitive isoform, being translocated at 1^10 nM TeTx, where-
as at 100 nM the total immunoreactivity decreases, revealing
the appearance of down-regulation. The response of PKC-Q
isoform was similar, although down-regulation appears at a
higher TeTx concentration (100 nM) (Fig. 2). On the other
hand, PKC-N showed a sustained translocation, without
down-regulation at any concentration tested. In the case of
the PKC-K isoform, a diminution in its total immunoreactiv-
ity (40% of diminution in the soluble fraction and 41% in the
particulate fraction) was detected at the highest concentration
tested (100 nM). No consistent translocation of PKC-O and
PKC-j following exposure of synaptosomes to TeTx was
found. Despite this, a slight diminution in the immunoreac-
tivity corresponding to the soluble fraction of PKC-O was
observed (38% diminution), whereas no increase in the partic-
ulate fraction occurs. This absence of translocation cannot be
attributed to either a saturation of the immunoblot technique
or an overexposure of the ¢lm during ECL detection. In order
to obtain internal control in PKC translocation experiments
TPA was included separately in each experiment (not shown).
3.3. TeTx stimulates tyrosine phosphorylation of trkA and of
PLCQ-1
To determine the possible e¡ect of TeTx on cellular signal
transduction pathways that involve Tyr phosphorylation, im-
munoprecipitation experiments using anti-phosphotyrosine
antibodies (clone PY20) were performed. In each experiment
whole synaptosomal homogenates were immunoprecipitated
using PY20 antibodies, and the contents of two proteins
which are phosphorylated in Tyr, i.e. trkA and PLCQ-1,
were determined, using speci¢c antibodies, by Western blot.
NGF was used as control of a typical signal transduction
activator (Fig. 3A). A single band corresponding to the
trkA receptor appeared at, approximately, 140 kDa of molec-
ular weight and a single band corresponding to PLCQ-1 at 150
kDa, both in accordance with the literature. This e¡ect was
not unspeci¢c, since the amount of signal due to FGFR-1
(¢broblast growth factor receptor-1) Tyr phosphorylation
was not altered (results not shown). The amount of Tyr phos-
phorylation which appeared in trkA and in PLCQ-1 is time-
dependent, the onset of the signal being rapid and detectable
after 1 min of treatment (Fig. 3A). In the two phosphopro-
teins tested, the maximal amounts of signal were seen in 10
min, whereas after 30 min the phosphorylation level had de-
creased. The PLCQ-1 phosphorylation was further supported
by our ¢nding that TeTx induces a modest but signi¢cant
polyphosphoinositide hydrolysis increase in rat brain synap-
tosomes, which is in agreement with PLC phosphorylation
and activation (manuscript submitted). Moreover, Western
analysis using a phospho-speci¢c antibody recognizing trkA
Fig. 3. TeTx-induced Tyr phosphorylation of trkA and PLCQ-1.
A: Synaptosomes in suspension in Krebs^Ringer bu¡er supple-
mented with 10 mM glucose were incubated at 30‡C with NGF
(50 nM) as positive control for 5 min or with 100 nM TeTx at dif-
ferent times. Equal amounts of lysate from each time point, ob-
tained by sonication and with a protein concentration of 1 mg/ml,
were immunoprecipitated, as described in Section 2, with 4 Wg of
antibody PY20 directed against phosphotyrosine residues, and blots
were probed with anti-trkA or anti-PLCQ-1. Each experiment was
repeated three times, and similar results were obtained. B: Time-
course of the TeTx-stimulated phosphorylation of trkA in Tyr-490.
The upper blot was incubated with phospho-speci¢c antibody for
phosphorylated trkA (Tyr-490). The lower blot shows immunoreac-
tivity obtained with antibody speci¢c for trkA, in a manner inde-
pendent of its phosphorylation state. Blots are representative of
three separate experiments.
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phosphorylated in Tyr-490 reveals a rapid increase of TeTx-
induced trkA phosphorylation, while signal decreasing is de-
tected at 30 min after treatment (Fig. 3B). Equal loading of
protein between samples was con¢rmed by detection with
phosphorylation state-independent anti-trkA. This result is
in agreement with the signal which appeared in immunopre-
cipitation experiments.
3.4. Enhancement of ERK-1/2 phosphorylation status and of
MAP kinase activity
A series of Western analysis using an antibody speci¢c for
dually Thr- and Tyr-phosphorylated ERK-1 (p44) and ERK-2
(p42) was performed (Fig. 4). In time-course experiments,
where synaptosomes were treated with TeTx (100 nM), an
induction of ERK phosphorylation was seen. The strongest
signal appeared after 10 min of treatment, being maintained in
the 30 min treatment. Equal loading of protein between sam-
ples was con¢rmed by detection with phosphorylation state-
independent anti-ERK-1, although this antibody recognizes
both p44 and p42 in the assayed conditions. The determina-
tion of MAPK activity present in the synaptosomal soluble
fraction, using myelin basic protein (MBP) as substrate, shows
an increase in MBP phosphorylation induced by TeTx, this
being slight at 10 nM (154%) and more marked at 100 nM
(245%) (Fig. 5).
4. Discussion
The in£uence of TeTx over some members of signal trans-
duction pathways has been described in several works. The
¢rst work on this topic described the decrease of PKC activ-
ity, in soluble fraction as well as in particulate fraction, in
TeTx-treated macrophages and in the spinal cord of mice
with generalized tetanus [21]. Our group described TeTx-in-
duced PKC activation/translocation and down-regulation
after intraventricular toxin administration into adult rats [6].
In perinatal rat brain, TeTx causes PKC activation parallel
with an increase of serotonin turnover [22,7]. Later, treatment
of rat brain primary neuronal cultures with the neurotoxin
revealed PKC activity translocation and increases in poly-
phosphoinositide hydrolysis [8]. In the present work, a de-
tailed investigation focusing on which PKC isoforms are af-
fected by TeTx is performed, observing a puzzling diminution
in total PKC-K immunoreactivity, which could be related to a
high degree of stimulus-triggered PKC hydrolysis detected in
rat brain synaptosomes [23]. PKC translocation observed in
some isoforms in this work is directly related to the activation
of PLCQ-1, since the phospholipase products (diacylglycerol
and inositol 1,4,5-triphosphate, as a calcium mobilizer) are
activators of PKC and induce its translocation. Moreover,
PLCQ-1 phosphorylation is in consonance with polyphospho-
inositide hydrolysis enhancement by TeTx observed in pri-
mary neuron cultures from fetal rat brain and in slices from
adult rat cerebral cortex [8]. This phospholipase C activity
increase, which is modest but signi¢cant, is very similar to
that exerted by NGF in rat brain synaptosomes [23]. In the
same work, an NGF-activated PKC-Q and -N translocation
was described, although PKC-L translocation was slight and
di⁄cult to detect. TeTx-stimulated inositol phospholipid hy-
drolysis has also been detected in rat brain synaptosomes, in a
comparable level to that exerted by NGF (results not shown).
NGF is a signaling molecule that acts through PLCQ activa-
tion [24], this speci¢c activation being related to the modest
increase of polyphosphoinositide hydrolysis. Additionally,
PKC activation in synaptosomes could be related to serotonin
transport inhibition caused by TeTx or by its HC fragment
[25], since serotonin transporter phosphorylation by PKC
causes a diminution in its transport capacity [26]. Studies
focusing on HC-TeTx-induced redistribution of PKC iso-
enzymes are now in progress in our group. On the other
hand, TeTx-induced phosphorylation of trkA in Tyr-490
points to a parallel association of shc proteins with the
trkA, an important event implicated in neuronal di¡erentia-
tion [27]. This putative association is strongly supported by
ERK-1/2 phosphorylation observed in this work, since the shc
adapter proteins are the ¢rst link of a pathway that results in
ERK-1/2 activation [12]. In addition, the activation of MAPK
pathway could explain the changes in the C-fos and Fos-like
immunoreactivity observed in the cortex of rats with tetanus
toxin-induced epilepsy [28], since growth factor-induced c-fos
expression is activated through transcription factors, such as
Elk-1 or SAP-1, that are targets of the ras/MAPK [29] or
PKC mediated phosphorylation [30].
Early studies show that TeTx binds to gangliosides contain-
Fig. 5. MAPK activity induction by TeTx, at 1, 10 and 100 nM
concentration. The MAPK activity present in the soluble fraction
was assessed at a ¢nal protein concentration of 10 Wg/ml using
[Q-32P]ATP and MBP as substrate, as described in Section 2. The re-
sults are expressed as means þ S.E.M. of the percentage of three sep-
arate experiments. Di¡erences between groups were assessed using
the one-way ANOVA test (P6 0.001) and one-way Dunnett’s test
for multiple comparisons. ‘*’ represents signi¢cantly di¡erent from
the control group (P6 0.05).
Fig. 4. Activation of ERK-1/2 by TeTx. Synaptosomes were incu-
bated at 30‡C with TeTx (100 nM) for di¡erent times in A or were
incubated at increasing TeTx concentration for 30 min in B. For
immunoblot 20 Wg/lane of total synaptosomal lysates were loaded in
each SDS^PAGE. Upper blots were analyzed using antibody speci¢c
for fully Thr- and Tyr-phosphorylated ERK-1 (p44) and ERK-2
(p42) (phospho-p44/42 MAP kinase E10 monoclonal antibody).
Lower blots show the immunoreactivity obtained for samples as in
upper blots with antibodies speci¢c for ERK-1 and -2, independent
of their phosphorylation state. All blots are representative of three
separate experiments.
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ing ‘1b’ structure, such as GT1b or GD1b with a high a⁄nity
[31]. Ganglioside binding has also been demonstrated for
Type A and for Type E Clostridium botulinum neurotoxins
[32]. On the other hand, the involvement of a protein compo-
nent has been postulated, since TeTx binding to cells and
neuronal membranes is sensitive to proteases [33]. According
to this, a two receptor model has been postulated in which the
initial toxin binding to gangliosides is followed by lateral
movement in the membrane until the toxin reaches a protein
receptor, then given internalization [34]. Despite e¡orts made,
the nature of the neurospeci¢c protein receptor of TeTx is still
unknown, although cross-linking experiments in NGF-di¡er-
entiated PC12 cells suggest that an N-glycosylated protein
with an apparent molecular weight of 15^20 kDa is involved
in the neurospeci¢c binding of TeTx [35,36]. Recently, the
binding of the HC fragment from BoNT/A, which shares the
feature with TeTx and with trk receptors of being retroaxo-
nally transported [37], to three proteins of approximately 150,
120 and 75 kDa of molecular mass in rat synaptosomes has
been reported [38].
In summary, this work determines di¡erential translocation
of synaptosomal PKC isoforms in response to TeTx. Like-
wise, this PKC activation is directly related to PLCQ-1 phos-
phorylation and to trkA activation, assessed by means of its
phosphotyrosine content. Furthermore, the downstream acti-
vation of MAP kinases ERK-1 and -2 also exists, displaying
part of a signal transduction pathway, whose complexity must
be assessed, triggered by TeTx. On the other hand, the inter-
action of TeTx with p140 trkA represents a mechanism by
which the toxin could take advantage of trkA mobility in its
tropism to the central nervous system. Further work, which is
in progress in our group, will shed light on the speci¢c rela-
tions between activation of signal proteins by TeTx and the
manner of action of this lethal toxin on the nervous system.
Acknowledgements: This work was supported in part by Grant PB97-
0169 from the Ministerio de Educacio¤n y Cultura, Direccio¤n General
de Ensen‹anza Superior e Investigacio¤n Cient|¤¢ca. We thank Salvador
Bartolome¤ from L.A.B. for technical assistance in image scanning and
¢gure presentation.
References
[1] Simpson, L.L. (1989) Botulinum Neurotoxin and Tetanus Toxin,
Academic Press, San Diego.
[2] Niemann, H., Blasi, J. and Jahn, R. (1994) Trends Cell Biol. 4,
179^185.
[3] Schiavo, G., Benfenati, F., Poulain, B., Rossetto, O., DeLaureto,
P.P., DasGupta, B.R. and Montecucco, C. (1992) Nature 359,
832^835.
[4] Schiavo, G., Poulain, B., Rossetto, O., Benfenati, F., Tauc, L.
and Montecucco, C. (1992) EMBO J. 11, 3577^3583.
[5] Facchiano, F., Valtorta, F., Benfeneti, F. and Luini, A. (1993)
Trends Biochem. Sci. 18, 327^329.
[6] Aguilera, J. and Yavin, E. (1990) J. Neurochem. 54, 339^342.
[7] Aguilera, J., Padro¤s-Giralt, C., Habig, W.H. and Yavin, E.
(1993) J. Neurochem. 60, 709^713.
[8] Gil, C., Ruiz-Meana, M., Alava, M., Yavin, E. and Aguilera, J.
(1998) J. Neurochem. 70, 1636^1643.
[9] Iban‹ez, C.F., Ebendal, T. and Persson, H. (1991) EMBO J. 10,
2105^2110.
[10] Barbacid, M. (1993) Oncogene 8, 2033^2042.
[11] Segal, R.A. and Greenberg, M.E. (1996) Annu. Rev. Neurosci.
19, 463^489.
[12] Seger, R. and Krebs, E.G. (1995) FASEB J. 9, 726^735.
[13] Robbins, D.J., Zhen, E., Owaki, H., Vanderbilt, C.A., Ebert, D.,
Geppert, T.D. and Cobb, M.H. (1993) J. Biol. Chem. 268, 5097^
5106.
[14] Nishizuka, Y. (1995) FASEB J. 9, 484^496.
[15] Nishizuka, Y. (1992) Science 9, 484^496.
[16] Kraft, A.S. and Anderson, W.B. (1983) Nature 301, 621^623.
[17] Saido, T.C., Sorimachi, H. and Suzuki, K. (1994) FASEB J. 8,
814^822.
[18] Yurko-Mauro, K.A. and Friedman, E. (1995) J. Neurochem. 65,
1622^1630.
[19] Gray, E.G. and Whittaker, U.P. (1962) J. Anat. 96, 1^36.
[20] Go¤mez, N., Tonks, N.K., Morrison, C., Harmar, T. and Cohen,
P. (1990) FEBS Lett. 271, 119^122.
[21] Ho, J.L. and Klempner, M.S. (1988) J. Infect. Dis. 157, 925^933.
[22] Aguilera, J., Lo¤pez, L.A. and Yavin, E. (1990) FEBS Lett. 263,
61^65.
[23] Gil, C., Pelliccioni, P., Itarte, E. and Aguilera, J. (1999) Neuro-
chem. Int. 35, 281^291.
[24] Ohmichi, M., Decker, S.J., Pang, L. and Saltiel, A.R. (1991)
Biochem. Biophys. Res. Commun. 179, 217^223.
[25] Najib, A., Pelliccioni, P., Gil, C. and Aguilera, J. (1999) J. Neu-
rochem. 72, 1991^1998.
[26] Ramamoorthy, S., Giovanetti, E., Qian, Y. and Blakely, R.D.
(1998) J. Biol. Chem. 273, 2458^2466.
[27] Obermeier, A., Bradshaw, R.A., Seedorf, K., Choidas, A.,
Schlessinger, J. and Ullrich, A. (1994) EMBO J. 13, 1585^1590.
[28] Liang, F. and Jones, E.G. (1997) Brain Res. 778, 281^292.
[29] Treisman, R. (1992) Trends Biochem. Sci. 17, 423^426.
[30] Hill, C.S. and Treisman, R. (1995) Cell 80, 199^211.
[31] Rogers, T.B. and Snyder, S.H. (1981) J. Biol. Chem. 256, 2402^
2407.
[32] Schengrund, C.L., DasGupta, B.R., Hughes, C.A. and Ringler,
N.J. (1996) J. Neurochem. 66, 2556^2561.
[33] Yavin, E. and Nathan, A. (1986) Eur. J. Biochem. 105, 403^407.
[34] Monteccuco, C. (1986) Trends Biochem. Sci. 18, 324^327.
[35] Schiavo, G., Ferrari, G., Rossetto, O. and Montecucco, C. (1991)
FEBS Lett. 290, 227^230.
[36] Herreros, J., Lalli, G., Montecucco, C. and Schiavo, G. (2000)
J. Neurochem. 74, 1941^1950.
[37] Wellho«ner, H.H. (1989) in: Botulinum Neurotoxin and Tetanus
Toxin (Simpson L.L., Ed.), pp. 231^253, Academic Press, San
Diego.
[38] Li, L. and Singh, B.R. (1999) J. Protein Chem. 18, 89^95.
FEBS 24113 8-9-00
C. Gil et al./FEBS Letters 481 (2000) 177^182182
